Basic treatment considerations using chemotherapy for patients with small cell lung cancer

Hematology/Oncology Clinics of North America

Volumn 18, Issue 2, 2004, Pages 309-322

  Johnson, Bruce E ^a,b,c   Jänne, Pasi A ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IMATINIB; IRINOTECAN; LOMUSTINE; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; METHOTREXATE; VINCRISTINE;

BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HEARING LOSS; HUMAN; HYPOTENSION; KIDNEY FAILURE; LUNG SMALL CELL CANCER; META ANALYSIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; RADIATION INDUCED EMESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION;

EID: 1942471677     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2003.12.008     Document Type: Review

References (67)

1. Barnard W.G. The nature of the "oat-celled sarcoma" of the mediastinum. J Pathol Bacteriol. 29:1926;241-244.
2. Travis W.D., Colby T.V., Corrin B., Shimosato Y., Brambilla E. Histological typing of lung and pleural tumours. 3rd edition:1999;Springer- Verlag, Berlin.
3. Hirsch F.R., Matthews M.J., Yesner R. Histopathologic classification of small cell carcinoma of the lung: comments based on an interobserver examination. Cancer. 50:1982;1360-1366.
4. Hirsch F.R., Matthews M.J., Aisner S., Campobasso O., Elema J.D., Gazdar A.F.et al. Histopathologic classification of small cell lung cancer: changing concepts and terminology. Cancer. 62:1988;973-977.
5. Janne P.A., Freidlin B., Saxman S., Johnson D.H., Livingston R.B., Shepherd F.A.et al. Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. Cancer. 95:2002;1528-1538.
6. Mountain C.F. Clinical biology of small cell carcinoma: relationship to surgical therapy. Sem Oncol. 5:1978;272-279.
7. Fox W., Scadding J.G. Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of the bronchus. Lancet. 2:1973;63-65.
8. Green R.A., Humphrey E., Close H., Patno M.E. Alkylating agents in bronchogenic carcinoma. Am J Med. 46:1969;516-525.
9. Johnson B.E., Ihde D.C., Bunn P.A., Becker B., Walsh T., Weinstein Z.R.et al. Patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation: data on potential cures, chronic toxicities, and late relapses after a five- to eleven-year follow-up. Ann Intern Med. 103:1985;430-438.
10. Osterlind K., Hansen H.H., Hansen M., Dombernowksy P. Mortality and morbidity in long-term surviving patients treated with chemotherapy with or without irradiation for small-cell lung cancer. J Clin Oncol. 4:1986;1044-1052.
11. Chu E., Devita V.T. Principles of cancer management: chemotherapy. Devita V.T., Hellman S., Rosenberg S.A. 6th edition Cancer: principles and practice of oncology. vol. 1:2001;289-333 Lippincott Williams and Wilkins, Philadephia.
12. Green S., Weiss G.R. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs. 10:1992;239-253.
13. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L.et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92:2000;205-216.
14. Korn E.L., Arbuck S.G., Pluda J.M., Simon R., Kaplan R.S., Christian M.C. Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol. 19:2001;265-272.
15. Grant S.C., Gralla R.J., Kris M.G., Orazem J., Kitsis E.A. Single-agent chemotherapy trials in small cell lung cancer, 1970 to 1990: the case for studies in previously treated patients. J Clin Oncol. 10:1992;484-498.
16. Moore T.D., Korn E.L. Phase II trial design considerations for small-cell lung cancer. J Natl Cancer Inst. 84:1992;150-154.
17. Kelly K. New chemotherapy agents for small cell lung cancer. Chest. 117:2000;156S-162S.
18. Ettinger D.S. New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer. Semin Oncol. 28:2001;27-29.
19. von Pawel J., Schiller J.H., Shepherd F.A., Fields S.Z., Kleisbauer J.P., Chrysson N.G.et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 17:1999;658-667.
20. Ardizzoni A., Hansen H., Dombernowsky P., Gamucci T., Kaplan S., Postmus P.et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol. 15:1997;2090-2096.
21. Johnson B.E., Fischer T., Fischer B., Dunlop D., Rischin D., Silberman S.et al. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res. 9:2003;5880-5887.
22. Micke P., Basrai M., Faldum A., Bittinger F., Ronnstrand L., Blaukat A.et al. Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. Clin Cancer Res. 9:2003;188-194.
23. Cohen M.H., Creaven P.J., Fossieck B.E. Jr., Broder L.E., Selawary O.S., Johnston A.V.et al. Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep. 3:1977;349-354.
24. Ihde D.C., Mulshine J.L., Kramer B.S., Steinberg S.M., Linnoila R.I., Gazdar A.F.et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol. 12:1994;2022-2034.
25. Arriagada R., Le Chevalier T., Pignon J.P., Riviere A., Monnet I., Chomy P.et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med. 329:1993;1848-1852.
26. Cavalli F., Sonntag R.W., Jungi F., Senn H.J., Brunner K.W. VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules. Cancer Treat Rep. 62:1978;473-475.
27. Abratt R.P., Willcox P.A., de Groot M., Goodman H.T., Jansen E.R., Salton D.G.M. Prospective study of etoposide scheduling in combination chemotherapy for limited disease small cell lung carcinoma. Eur J Cancer. 27:1991;28-30.
28. Slevin M.L., Clark P.I., Joel S.P., Malik S., Osborne R.J., Gregory W.M.et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol. 7:1989;1333-1340.
29. Turrisi A.T. III, Kim K., Blum R., Sause W.T., Livingston R.B., Komaki R.et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide [see comments]. N Engl J Med. 340:1999;265-271.
30. Miller A.A., Herndon J.E. II, Hollis D.R., Ellerton J., Langleben A., Richards F. IIet al. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. J Clin Oncol. 13:1995;1871-1879.
31. Bonner J.A., Sloan J.A., Shanahan T.G., Brooks B.J., Marks R.S., Krook J.E.et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol. 17:1999;2681-2691.
32. Crawford J., Ozer H., Stoller R., Johnson D.H., Lyman G., Tabbara I.et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 325:1991;164-170.
33. Steward W.P., von Pawel J., Gatzemeier U., Woll P., Thatcher N., Koschel G.et al. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. J Clin Oncol. 16:1998;642-650.
34. Thatcher N., Girling D.J., Hopwood P., Sambrook R.J., Qian W., Stephens R.J. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council multicenter randomized trial. Medical Research Council Lung Cancer Working Party. J Clin Oncol. 18:2000;395-404.
35. Ardizzoni A., Tjan-Heijnen V.C., Postmus P.E., Buchholz E., Biesma B., Karnicka-Mlodkowska H.et al. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. J Clin Oncol. 20:2002;3947-3955.
36. Murray N., Livingston R.B., Shepherd F.A., James K., Zee B., Langleben A.et al. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an intergroup study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol. 17:1999;2300-2308.
37. Furuse K., Fukuoka M., Kawahara M., Nishikawa H., Takada Y., Kudoh S.et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 17:1999;2692-2699.
38. Pignon J.P., Arriagada R., Ihde D.C., Johnson D.H., Perry M.C., Souhami R.L.et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 327:1992;1618-1624.
39. Warde P., Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol. 10:1992;890-895.
40. Murray N., Coy P., Pater J.L., Hodson I., Arnold A., Zee B.C.et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol. 11:1993;336-344.
41. Takada M., Fukuoka M., Kawahara M., Sugiura T., Yokoyama A., Yokota S.et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol. 20:2002;3054-3060.
42. Jeremic B., Shibamoto Y., Acimovic L., Milisavljevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol. 15:1997;893-900.
43. Turrisi A.T.I., Glover D.J., Mason B.A. A preliminary report: concurrent twice-daily radiotherapy plus platinum-etoposide chemotherapy for limited small cell lung cancer. Int J Radiat Oncol Biol Phys. 15:1988;183-187.
44. Choi N.C., Herndon J.E. II, Rosenman J., Carey R.W., Chung C.T., Bernard S.et al. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol. 16:1998;3528-3536.
45. Johnson B.E., Bridges J.D., Sobczeck M., Gray J., Linnoila R.I., Gazdar A.F.et al. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J Clin Oncol. 14:1996;806-813.
46. Bunn P.A., Lichter A.S., Makuch R.W., Cohen M.H., Veach S.R., Matthews M.J.et al. Chemotherapy alone or chemotherapy with chest irradiation therapy in limited stage small cell lung cancer. Ann Intern Med. 106:1987;655-662.
47. Perry M.C., Eaton W.L., Propert K.J., Ware J.H., Zimmer B., Chahinian A.P.et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med. 316:1987;912-918.
48. Sundstrom S., Bremnes R.M., Kaasa S., Aasebo U., Hatlevoll R., Dahle R.et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol. 20:2002;4665-4672.
49. Noda K., Nishiwaki Y., Kawahara M., Negoro S., Sugiura T., Yokoyama A.et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 346:2002;85-91.
50. Ilson D.H., Bains M., Kelsen D.P., O'Reilly E., Karpeh M., Coit D.et al. Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. J Clin Oncol. 21:2003;2926-2932.
51. Yamada M., Kudoh S., Fukuda H., Nakagawa K., Yamamoto N., Nishimura Y.et al. Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer. Br J Cancer. 87:2002;258-263.
52. Schiller J.H., Adak S., Cella D., DeVore R.F. III, Johnson D.H. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593 - a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 19:2001;2114-2122.
53. Sandler A.B. Chemotherapy for small cell lung cancer. Semin Oncol. 30:2003;9-25.
54. Nelson A.R., Fingleton B., Rothenberg M.L., Matrisian L.M. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 18:2000;1135-1149.
55. Hidalgo M., Eckhardt S.G. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst. 93:2001;178-193.
56. Shepherd F.A., Giaccone G., Seymour L., Debruyne C., Bezjak A., Hirsh V.et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol. 20:2002;4434-4439.
57. Grant S.C., Kris M.G., Houghton A.N., Chapman P.B. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. Clin Cancer Res. 5:1999;1319-1323.
58. Patel J.D., Krug L.M., Azzoili C.G., Gomez J., Kris M.G., Miller V.A. Targeting lethal minimal residual disease in small cell lung cancer. Semin Oncol. 30:2003;79-85.
59. Lacroix J., Becker H.D., Woerner S.M., Rittgen W., Drings P., von Knebel Doeberitz M. Sensitive detection of rare cancer cells in sputum and peripheral blood samples of patients with lung cancer by preproGRP-specific RT-PCR. Int J Cancer. 92:2001;1-8.
60. Saito T., Kobayashi M., Harada R., Uemura Y., Taguchi H. Sensitive detection of small cell lung carcinoma cells by reverse transcriptase-polymerase chain reaction for prepro-gastrin-releasing peptide mRNA. Cancer. 97:2003;2504-2511.
61. Saltz L.B., Minsky B. Adjuvant therapy of cancers of the colon and rectum. Surg Clin N Am. 82:2002;1035-1058.
62. Legare R.D., Strenger R. Adjuvant therapy in breast cancer. Obstet Gynecol Clin N Am. 29:2002;201-208. ix.
63. Rea F., Callegaro D., Favaretto A., Loy M., Paccagnella A., Fantoni U.et al. Long term results of surgery and chemotherapy in small cell lung cancer. Eur J Cardiothorac Surg. 14:1998;398-402.
64. Szczesny T.J., Szczesna A., Shepherd F.A., Ginsberg R.J. Surgical treatment of small cell lung cancer. Semin Oncol. 30:2003;47-56.
65. Johnson B.E. NCCN Small Cell Lung Cancer Practice Guidelines Panel NCCN: small cell lung cancer. Cancer Control. 8:2001;32-43.
66. Evans W.K., Feld R., Murray N., Willan A., Coy P., Osaba D.et al. Superiority of alternating non-cross-resistant chemotherapy in extensive stage small cell lung cancer. Ann Intern Med. 107:1987;451-458.
67. Feld R., Evans W.K., Coy P., Hodson I., MacDonald A.S., Osaba D.et al. Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J Clin Oncol. 5:1987;1401-1409.